A growing body of evidence suggests that a rare epithelial cell type known as the tuft cell may play a far more significant role in cancer than previously recognized. A recent review proposes that tumors expressing the tuft cell master regulator POU2F3 represent a distinct molecular class of "tuft cell-like" cancers spanning multiple organs, including the lung, pancreas, stomach, colon, breast, prostate, and neuroendocrine tissues. These tumors exhibit unique biological characteristics that may create new opportunities for diagnosis, prognosis, and targeted therapy.
Tuft cells are specialized chemosensory epithelial cells normally found in tissues exposed to the external environment, such as the respiratory and gastrointestinal tracts. Beyond sensing environmental stimuli, they regulate immune responses through signaling molecules including interleukin-25 (IL-25). Central to tuft cell identity is the transcription factor POU2F3, which functions as a lineage-defining regulator controlling tuft cell differentiation and maintenance.
Using data from The Cancer Genome Atlas (TCGA), the authors analyzed POU2F3 expression across 33 cancer types. As illustrated in the expression analyses on pages 3–4, several cancers—including cervical squamous cell carcinoma, cholangiocarcinoma, esophageal carcinoma, stomach adenocarcinoma, and thyroid carcinoma—show significantly elevated POU2F3 levels compared with normal tissue. In contrast, reduced expression was observed in prostate and kidney cancers as well as head and neck squamous cell carcinoma. These findings support the existence of tumor-specific tuft cell-like programs across a wide spectrum of malignancies.
The review highlights particularly strong evidence in small cell lung cancer (SCLC), where POU2F3 defines a distinct non-neuroendocrine subtype. These tumors depend on tuft cell-associated transcriptional networks for survival and display molecular vulnerabilities that may be therapeutically exploitable. Similar tuft cell-like signatures have also been identified in lung adenocarcinoma, pulmonary squamous cell carcinoma, and thymic squamous cell carcinoma, suggesting that POU2F3 expression may define clinically meaningful tumor subgroups.
In pancreatic cancer, tuft cells appear to play a complex dual role. Early in disease development they may suppress tumor formation through production of prostaglandin D₂ (PGD₂). However, under the influence of oncogenic KRAS signaling and inflammatory pathways, tuft cells can contribute to tumor progression and acquire stem cell-like properties associated with treatment resistance. Recent evidence suggests that pancreatic tuft cells may even transdifferentiate into neural-like progenitor cells linked to poor clinical outcomes.
The review also identifies important functions for tuft cells in colorectal and gastric cancers. In colorectal cancer, tuft cell-associated signaling promotes immune suppression and supports cancer stem cell populations that drive metastasis. In gastric cancer, tuft cells participate in cholinergic signaling networks involving acetylcholine and nerve growth factor, pathways that have been shown to promote tumor development. Disrupting these signaling circuits has demonstrated anti-tumor effects in experimental models.
Clinical analyses revealed that the prognostic value of POU2F3 is highly context dependent. High expression was associated with shorter overall survival in thymoma, while in breast cancer the adverse prognostic effect was observed specifically in patients with stage III disease, as shown in the survival analyses presented on page 6. These findings suggest that tuft cell-related biology may become increasingly important during tumor progression.
